BridgeBio Pharma, Inc. (FRA:2CL)

Market Cap	11.15B +83.2%
Revenue (ttm)	301.53M +62.5%
Net Income	-679.38M
EPS	-3.57
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	97
Open	59.74
Previous Close	60.58
Day's Range	58.48 - 59.74
52-Week Range	24.53 - 72.80
Beta	n/a
RSI	42.44
Earnings Date	Feb 24, 2026

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 728
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2CL

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Financial numbers in USD